rs121434288 — SLC39A4 SLC39A4 zinc transporter variant

Pathogenic missense variant in the ZIP4 intestinal zinc transporter causing hereditary acrodermatitis enteropathica when homozygous; heterozygotes are asymptomatic carriers

See your personal result for SLC39A4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC39A4 G501R — The ZIP4 Zinc Transporter Variant

Every cell in the body needs zinc for more than 300 enzymes and 2,000+ transcription factors, yet the human body has no dedicated zinc storage organ — it must be continuously absorbed from food. In the intestine, most of that absorption flows through a single gateway: ZIP411 ZIP4
The Zrt/Irt-like protein 4, encoded by SLC39A4 on chromosome 8q24.3, is the primary zinc importer on the apical surface of duodenal and jejunal enterocytes. When both copies of the SLC39A4 gene are non-functional, dietary zinc simply cannot cross the gut wall. The result — hereditary acrodermatitis enteropathica (AE) — is a severe systemic zinc deficiency that is uniformly fatal without treatment but fully manageable with lifelong oral zinc supplementation.

The rs121434288 variant (c.1576G>A on the coding strand; C>T on the GRCh38 plus strand) replaces glycine at position 501 of the mature ZIP4 protein with arginine. Glycine 501 sits within the fifth transmembrane domain of ZIP4, adjacent to a histidine residue at position 536 that is conserved throughout the ZIP transporter family and essential for zinc coordination. The Gly→Arg substitution introduces a bulky, positively charged residue into the membrane-spanning helix, almost certainly disrupting the protein's three-dimensional structure and eliminating zinc transport activity.

The Mechanism

ZIP4 is expressed on the apical (luminal-facing) membrane of enterocytes, with expression upregulated in response to zinc deficiency. Its function is to move zinc ions from the intestinal lumen into the absorptive cells, from where zinc enters the circulation. The Gly501Arg missense disrupts the structural integrity of ZIP4's transmembrane channel. Because AE is autosomal recessive22 autosomal recessive
Both copies of the gene must be non-functional for disease to occur; one functional copy is sufficient for normal zinc absorption, a single defective copy has no measurable impact on zinc status. Homozygotes — who inherit the variant from both parents — lose all functional ZIP4 activity, reducing intestinal zinc absorption to a fraction of normal. Since the body cannot synthesize or store meaningful zinc reserves, systemic zinc deficiency develops rapidly, within the first weeks of life in affected infants.

The Evidence

Küry et al. (2002)33 Küry et al. (2002)
Küry S et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nature Genetics, 2002 identified SLC39A4 as the AE gene through positional cloning and mutational analysis of eight affected families. The Gly501Arg variant (reported in their study as c.1501G>A in the then-current reference sequence; now annotated as c.1576G>A / p.Gly526Arg in isoform 2, or p.Gly501Arg in the canonical isoform) was found in homozygous form in two brothers with classic AE phenotype. The authors noted the variant's location near the conserved His536 residue known to be required for metal co-ordination in ZIP-family transporters.

A comprehensive mutation update by Schmitt et al. (2009)44 Schmitt et al. (2009)
Schmitt S et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Human Mutation, 2009 catalogued 31 pathogenic SLC39A4 variants across AE patients, confirming that missense mutations are the most common type and are distributed throughout the gene. The Gly501Arg variant is among the most structurally damaging — the substitution of glycine (the smallest amino acid, enabling tight membrane helix packing) with arginine (large and positively charged) in a transmembrane segment is predicted to severely disrupt ZIP4 folding and function.

Clinically, untreated AE presents in formula-fed infants within the first 4–10 weeks of life with a triad of acral and perioral dermatitis, diarrhoea, and alopecia. Breast-fed infants are typically protected by the high bioavailability of zinc in breast milk and present upon weaning. Without zinc supplementation, affected infants fail to thrive and the disease is fatal.

Practical Implications

Oral zinc supplementation fully corrects the phenotype in homozygous AE patients. Treatment is initiated at 5–10 mg/kg/day of elemental zinc during the acute phase, then reduced to a maintenance dose of 1–2 mg/kg/day for life. Doses must be adjusted upward during growth phases, illness, and pregnancy. Regular monitoring of serum zinc is essential to avoid both deficiency relapses and zinc toxicity from over-supplementation.

Carriers (heterozygotes) are clinically unaffected under normal dietary conditions, but this variant is important for family planning: two carrier parents have a 25% probability of having an affected child with each pregnancy.

Interactions

AE illustrates how completely the body's zinc economy depends on ZIP4. Variants in other SLC39A (ZIP family) and SLC30A (ZnT family) genes modulate zinc homeostasis but do not cause AE. Dietary factors that affect zinc bioavailability — particularly phytates in cereals and legumes, which form insoluble zinc complexes — are especially relevant for heterozygous carriers whose single functional ZIP4 copy must work efficiently. Co- administration of oral zinc with quinolone antibiotics (ciprofloxacin) or tetracyclines (doxycycline) should be timed to avoid chelation interactions that reduce absorption of both compounds.

Nutrient Interactions

zinc reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

CC Non-carrier Normal

Both SLC39A4 copies functional — normal zinc absorption

You carry two copies of the wild-type C allele at rs121434288. Your ZIP4 zinc transporter is fully functional, and intestinal zinc absorption operates normally. You are not a carrier of this acrodermatitis enteropathica-associated variant. This genotype represents the vast majority of the global population; the T (pathogenic) allele is vanishingly rare in all studied populations.

CT Carrier Carrier

Carrier of one SLC39A4 pathogenic allele

Autosomal recessive inheritance means that acrodermatitis enteropathica (AE) requires loss of both SLC39A4 copies. A single functional copy of ZIP4 provides adequate zinc transport for normal zinc homeostasis. Carrier status therefore does not require zinc supplementation or dietary modifications. The clinical relevance is confined to reproductive planning: genetic counselling is recommended for carriers, particularly if their partner is of the same ethnic background or has a family history of AE. Prenatal or pre-implantation genetic testing can identify affected pregnancies.

TT Homozygous Homozygous

Homozygous — ZIP4 zinc transporter non-functional; lifelong zinc supplementation required

Acrodermatitis enteropathica is characterised by the classic triad of dermatitis (eczematous plaques around the mouth, eyes, and extremities), diarrhoea, and alopecia, typically presenting in the first 4–10 weeks of life in formula-fed infants (breast- fed infants are protected by the high zinc bioavailability of breast milk and typically present at weaning). Additional features include failure to thrive, mood disturbances, photophobia, poor wound healing, and impaired immune function.

The disorder results directly from inability to transport zinc across the intestinal epithelium. Without adequate zinc, more than 300 metalloenzymes fail to function properly, affecting virtually every organ system.

Treatment is straightforward and highly effective: oral zinc supplementation bypasses the impaired transporter by saturating passive diffusion mechanisms. Zinc gluconate, zinc sulphate, and zinc acetate are all used successfully. The goal is to maintain serum zinc within the normal reference range (70–120 µg/dL / 10.7–18.4 µmol/L) while avoiding toxicity. Dose requirements increase during growth spurts, acute illness, and pregnancy, and must be monitored accordingly throughout life.

Note: If you have this result from a consumer genotyping chip, be aware that this is a very rare variant and confirm with a clinical genetic test. Compound heterozygosity (one Gly501Arg allele plus a different SLC39A4 pathogenic allele on the other chromosome) also causes AE and would appear as CT rather than TT at this position.